Table 1.
Patients characteristics at baseline.
| Characteristic | Total | Non-MCEs | MCEs | p-Value | |||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Sex | 0.647 | ||||||
| Male | 318 | 89.6 | 306 | 89.7 | 12 | 85.7 | |
| Female | 37 | 10.4 | 35 | 10.3 | 2 | 14.3 | |
| Age | 0.780 | ||||||
| <65 | 222 | 62.5 | 214 | 62.8 | 8 | 57.1 | |
| ≥65 | 133 | 37.5 | 127 | 37.2 | 6 | 42.9 | |
| ECOG | 0.586 | ||||||
| 0 | 148 | 41.7 | 141 | 41.3 | 7 | 50.0 | |
| 1–2 | 207 | 58.3 | 200 | 58.7 | 7 | 50.0 | |
| History of Smoking | 0.564 | ||||||
| Yes | 236 | 66.5 | 228 | 66.9 | 8 | 57.1 | |
| No | 119 | 33.5 | 113 | 33.1 | 6 | 42.9 | |
| BMI, kg/m2 | 0.587 | ||||||
| <30 | 206 | 58.0 | 199 | 58.4 | 7 | 50.0 | |
| ≥30 | 149 | 42.0 | 142 | 41.6 | 7 | 50.0 | |
| History of CAD | 0.708 | ||||||
| Yes | 57 | 16.1 | 54 | 15.8 | 3 | 21.4 | |
| No | 298 | 83.9 | 287 | 84.2 | 11 | 78.6 | |
| History of Hyperlipidemia | 0.005 | ||||||
| Yes | 200 | 56.3 | 187 | 54.8 | 13 | 92.9 | |
| No | 155 | 43.7 | 154 | 45.2 | 1 | 7.1 | |
| History of Hypertension | 0.090 | ||||||
| Yes | 218 | 61.4 | 206 | 60.4 | 12 | 85.7 | |
| No | 137 | 38.6 | 135 | 39.6 | 2 | 14.3 | |
| History of Diabetes | 0.775 | ||||||
| Yes | 89 | 25.1 | 86 | 25.2 | 3 | 21.4 | |
| No | 266 | 74.9 | 255 | 74.8 | 11 | 78.6 | |
| Tumor Location | 0.180 | ||||||
| Upper/Middle | 38 | 10.7 | 35 | 10.3 | 3 | 21.4 | |
| Distal/GEJ | 317 | 89.3 | 306 | 89.7 | 11 | 78.6 | |
| Pathology | 0.065 | ||||||
| Adenocarcinoma | 314 | 88.5 | 304 | 89.1 | 10 | 71.4 | |
| SCC | 41 | 11.5 | 37 | 10.9 | 4 | 28.6 | |
| Clinical T Stage (7th) | 0.377 | ||||||
| T1–2 | 37 | 10.4 | 37 | 10.9 | 0 | 0.0 | |
| T3–4 | 318 | 89.6 | 304 | 89.1 | 14 | 100.0 | |
| Clinical N Stage (7th) | 0.773 | ||||||
| N0 | 113 | 31.8 | 108 | 31.7 | 5 | 35.7 | |
| N+ | 242 | 68.2 | 233 | 68.3 | 9 | 64.3 | |
| Clinical Stage (7th) | 1.000 | ||||||
| Stage I/II | 122 | 34.4 | 117 | 34.3 | 5 | 35.7 | |
| Stage III | 233 | 65.6 | 224 | 65.7 | 9 | 64.3 | |
| Induction Chemotherapy | 0.592 | ||||||
| Yes | 127 | 35.8 | 123 | 36.1 | 4 | 28.6 | |
| No | 228 | 64.2 | 218 | 63.9 | 10 | 71.4 | |
| Surgery | 0.578 | ||||||
| Yes | 215 | 60.6 | 208 | 61.0 | 7 | 50.0 | |
| No | 140 | 39.4 | 133 | 39.0 | 7 | 50.0 | |
| Radiotherapy Modality | 0.397 | ||||||
| IMRT | 234 | 65.9 | 223 | 65.4 | 11 | 78.6 | |
| PBT | 121 | 34.1 | 118 | 34.6 | 3 | 21.4 | |
| PTV | 1.000 | ||||||
| <600 cc | 173 | 48.7 | 166 | 48.7 | 7 | 50.0 | |
| ≥600 cc | 182 | 51.3 | 175 | 51.3 | 7 | 50.0 | |
| Platin-based Chemotherapy | 0.581 | ||||||
| Yes | 144 | 59.4 | 137 | 40.2 | 7 | 50.0 | |
| No | 211 | 40.6 | 204 | 59.8 | 7 | 50.0 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CAD, coronary artery disease; GEJ, gastroesophageal junction; SCC, squamous cell carcinoma; IMRT, intensity-modulated radiation therapy; PBT, proton beam therapy; PTV, Planning Target Volume.